NEW YORK (GenomeWeb) – Quest Diagnostics and Myriad Genetics have settled their patent dispute related to BRCA testing.

Myriad along with its co-patent holders and Quest have agreed to "dismiss their lawsuits, claims, counterclaims, and disputes related to Myriad's patent claims on BRCA1 and BRCA2 in the litigation," Quest said in a statement today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.